Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

NuVasive Falls After Revenue Is Less Than Forecast

NuVasive Inc. declined the most ever after the maker of orthopedic devices said third-quarter revenue was less than the company anticipated.

NuVasive fell 33 percent to $15.19 at the close of New York trading, the biggest drop since May 2004. The San Diego-based company has risen 21 percent this year.

Preliminary revenue was about $147 million, less than company expectations for a similar level as the $154.4 million posted in the second quarter, NuVasive said yesterday. Sales were hurt by competitor discounts and increased delays and denials of coverage by insurers, the device maker said.

“The miss was surprising and calls into question NuVasive’s” growth prospects, said Richard Newitter, a New York-based analyst for Leerink Swann & Co., in a note to investors today. The third-quarter sales were “well short of expectations,” he wrote.

Analysts at Brean Murray Carret & Co., BMO Capital Markets, Wells Fargo Securities and RBC Capital Markets reduced their ratings on NuVasive. Newitter has an outperform rating on the shares.

Full results for the third quarter will be released Oct. 29, the company said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.